Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments
Makaleler > Tam Makale · 2025
Yazarlar: Bernardo Sousa‐Pinto, Jean Bousquet, Rafael José Vieira, Holger J. Schünemann, Torsten Zuberbier, Antonio Bognanni, Alkis Togias, Boleslaw Samolinski, Arunas Valiulis, Sian Williams, Anna Bedbrook, Wienczyslawa Czarlewski, Maria Jose Torres, Mohamed H. Shamji, Mário Morais‐Almeida, G. Walter Canonica, Leticia de las Vecillas, Mark S. Dykewicz, Cristina Jacomelli, Ludger Klimek, Lucas Leemann, Olga Lourenço, Yuliia Palamarchuk, Nikolaos G. Papadopoulos, Ana Margarida Pereira, Marine Savouré, Sanna K. Toppila‐Salmi, Maria Teresa Ventura, Juan José Yepes‐Nuñez, Alvaro A. Cruz, Giorgio Ciprandi, Bilun Gemicioglu, Mattia Giovannini, Brigita Gradauskiene, Tuomas Jartti, Miloš Jeseňák, Piotr Kuna, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Amir HA Latiff, Yousser Mohammad, Ken Ohta, Padukudru A. Mahesh, Isabella Pali‐Schöll, Oliver Pfaar, Frederico S. Regateiro, Nicolas Roche, Luís Taborda‐Barata, Charlotte Suppli Ulrik, Marylin Valentin Rostan, Giovanni Viegi, Luo Zhang, Tari Haahtela, Ivan Cherrez‐Ojeda, Juan Carlos Ivancevich, Nikolai Khaltaev, Arzu Yorgancioglu, Baharudin Abdullah, Mona Al‐Ahmad, Maryam Ali Al‐Nesf, Rita Amaral, Julijana Asllani, Karl‐C Bergmann, Jonathan A. Bernstein, Michael S. Blaiss, Fulvio Braido, Paulo Camargos, Pedro Carreiro‐Martins, Thomas Casale, Lorenzo Cecchi, Alessandro Fiocchi, Antonio F. M. Giuliano, George Christoff, Ieva Cirule, Jaime Correia de Sousa, Elisio M. Costa, Stefano Del Giacco, Philippe Devillier, Dejan Dokic, Elham Hossny, Tomohisa Iinuma, Carla Irani, Zhanat Ispayeva, Kaja Julge, Igor Kaidashev, Kazi S. Bennoor, Helga Kraxner, Inger Kull, Marek Kulus, Maciej Kupczyk, Andriy Kurchenko, Stefania La Grutta, Neven Miculinic, Lan Le Thi Tuyet, Michael Makris, Branislava Milenkovic, Sang Min Lee, Stephen Montefort, Andre Moreira, Joaquim Mullol, Özlem GÖKSEL
Allergy, Uluslararası, Wos, 2025, cilt 81, ss 954-976
DOI: 10.1111/all.70131
Özet
BACKGROUND: Allergic rhinitis (AR) impacts quality of life, work and school productivity. Over the last years, an important body of evidence resulting from mHealth data has led to a better understanding of AR. Such advances have motivated an EAACI-endorsed update of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (ARIA 2024-2025). This manuscript presents the ARIA 2024-2025 recommendations for intranasal treatments, one of the mainstays for AR management. METHODS: The ARIA 2024-2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence-to-decision framework. Several sources of evidence were used to inform panel judgments and recommendations, including systematic reviews, evaluation of mHealth and pharmacovigilance data, as well as a survey of experts on costs. RESULTS: Eleven guideline questions concerning intranasal treatments for AR were prioritized, leading to recommendations. Overall, these questions concern the choice between different classes of intranasal medications-most notably, intranasal corticosteroids (INCS), antihistamines (INAH), fixed combinations of INAH+INCS and decongestants-or between different individual medications within each class. Four questions had not been evaluated in previous ARIA guidelines, while for the other three there was a change in the strength or directionality of recommendations. Overall, recommendations point to the suggested use of INAH+INCS over INAH or INCS and INCS over INAH. CONCLUSION: This ARIA 2024-2025 article supports patients, their caregivers, and healthcare professionals in choosing an intranasal treatment. However, decisions on AR treatment should consider the clinical variability of the disease, patients' values, and the affordability of medications.